Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Obesity Right
  3. Zepbound (tirzepatide) injection Right
  4. Are there any differences in injection site reactions with Zepbound® (tirzepatide) administered from a vial versus the single-dose pen?
Search Zepbound (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Zepbound ® (tirzepatide) injection

2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Are there any differences in injection site reactions with Zepbound® (tirzepatide) administered from a vial versus the single-dose pen?

There are no data available on injection site reactions with tirzepatide administered from a single-dose vial. Tirzepatide from the single dose vial and single-dose pen have the same drug formulation and analytical attributes.

US_cFAQ_TZPCWM362_INJECTION_SITE_REACTION_VIAL_VS_SINGLE_USE_PEN_CWM
US_cFAQ_TZPCWM362_INJECTION_SITE_REACTION_VIAL_VS_SINGLE_USE_PEN_CWMen-US

See important safety information, including boxed warning, in the attached prescribing information.

Injection Site Reactions With Tirzepatide Vial Versus Single-Dose Pen

In the SURMOUNT-1 and -2 phase 3 studies in adults with obesity or overweight, tirzepatide was administered through subcutaneous injection using a single-dose pen.1,2

In SURMOUNT-1 and -2, injection site reactions were reported in

  • 6% of participants receiving tirzepatide 5 mg, 
  • 8% of participants receiving tirzepatide 10 mg, 
  • 8% of participants receiving tirzepatide 15 mg, and 
  • 2% of participants receiving placebo.3 

Injection site reactions included multiple related adverse event terms, such as injection site bruising, injection site erythema, injection site pruritus, injection site pain, injection site rash, injection site reaction.3

There are no data available on injection site reactions with tirzepatide administered from a single-dose vial.

Tirzepatide provided in a single-dose vial and the single-dose pen have the same drug formulation.3

This includes the same excipients, excipient concentrations, and drug substance concentration.3

Dose strengths, injection volume, and route of administration are also the same.3

Both the tirzepatide single-dose vial and single-dose pen are for single use and do not contain preservatives.3

Tirzepatide provided in a single-dose vial and a single-dose pen also has the same analytical attributes, including specification tests and acceptance criteria.4

Enclosed Prescribing Information

ZEPBOUND® (tirzepatide) injection, for subcutaneous use, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038

2Garvey WT, Frias JP, Jastreboff AM, et al; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. https://doi.org/10.1016/S0140-6736(23)01200-X

3Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

4Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: June 07, 2024

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.44 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly